# Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)

> **NCT05282901** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Institut Curie** · enrollment: 51 (actual)

## Conditions studied

- Metastatic Uveal Melanoma

## Interventions

- **DRUG:** Pembrolizumab 25 MG/1 ML Intravenous Solution

## Key facts

- **NCT ID:** NCT05282901
- **Lead sponsor:** Institut Curie
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-07
- **Primary completion:** 2026-10-30
- **Final completion:** 2026-11-15
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2025-11-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05282901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05282901, "Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05282901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*